Registered User? Login
Major breakthroughs in healthcare – from cell and gene therapies to mRNA vaccines – have highlighted the power and value of investing in biopharma innovation. However, with the average cost of developing new drugs now exceeding US$2bn per therapy, raising funds for new programmes continues to be challenging.
Against a backdrop of ongoing cost pressures, competition to attract the right skills, and a strict regulatory environment, it has become tough to raise money for new product development over the past two years. Capital allocation is being put under the spotlight, with decision makers scrutinising how to achieve higher returns, whether to reallocate spending, and how to redesign business and partnership models.
The Financial Times, in partnership with Syneos Health, brought innovators and investors together to discuss the funding and partnership models that can accelerate drug discovery and breakthroughs in clinical development. Live from Boston, we explored how to de-risk investments in new pharma and biotech products and discussed the latest strategies for investing in clinical innovations.
De-risking investment to deliver innovation
What steps are key bio and pharma stakeholders taking to de-risk investment?
The marriage of biotech innovators and big pharma
How can dynamic and creative investment and partnership models advance promising innovations?
An investor’s perspective of strategy and value creation
What factors are financiers considering when making decisions about whether to invest?
© Financial Times Live
FT Live and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice
